ALKEM LABORATORIES: USFDA ISSUES WARNING LETTER TO AMALIYA'S DAMAN FACILITY FOLLOWING OAI CLASSIFICATION
ALKEM: Daman warning letter adds US supply risk, but the full impact is not yet clear
Price
₹5,145.5
Day change
-1.47%
P/E
29.73
ROE
13.91%
The USFDA warning letter follows an for Alkem’s Amaliya Daman facility. The story says the facility represents —a meaningful exposure, though not the whole business. Alkem has said it continues to manufacture and supply approved products from the facility and sees no material impact on current operations or finances; that statement does not, by itself, resolve the regulatory risk.
OAI classification
45% of US revenue and about 9.2% of total revenue
Evidence: price action and chart
At 2:32 pm IST on 19 November 2026, ALKEM was trading at ₹5,145.50, down 1.47% on the day, with the market open. Its 1-year chart shows a 10.19% decline over the period. The chart’s technical indicators describe the trend as bearish: price is below the 20-, 50- and 200-day averages, near ₹5,183, ₹5,202 and ₹5,406, respectively. Chart-derived reference levels are around ₹5,030 support and ₹5,301 resistance; these are indicators, not guaranteed turning points.
The shares are between the reported 52-week low of ₹4,811 and high of ₹5,933.50. Today’s decline and the chart’s weaker trend provide market context, but they do not establish how much of the move is attributable to the FDA action.
Business and regulatory implications
The key issue is whether the warning letter leads to restrictions, delays, or additional remediation requirements affecting products made at Daman. If supply or approvals are disrupted, the facility’s stated share of US revenue makes the exposure material; the effect on total company revenue would depend on the products involved, inventory, alternative manufacturing capacity, and the duration of any disruption. Those details are not available in the cited story or data retrieved here.
The distinction between OAI classification and a subsequent warning letter matters: the letter signals unresolved compliance concerns, but does not by itself quantify lost sales or confirm a shutdown. Alkem’s reported statement that supply continues is a relevant near-term mitigating fact, not proof that future supply is assured.
Fundamentals: valuation, profit and balance sheet
The fundamentals snapshot reports a P/E of about 29.7 and P/B of 4.18. It also reports EV/EBITDA of 17.59, below the sector figure of 22.8, while ROE (13.91%) and ROCE (17.87%) are above the sector values in that dataset. These ratios give valuation context, but do not price in any specific outcome from the regulatory action.
Annual consolidated results show FY26 revenue of ₹15,296 crore, up 13.65%, and net profit of ₹2,353 crore, up 6.19%. Net margin eased to 15.38% from 16.47% in FY25. That annual trend should be read alongside recent news: Alkem’s Q2 FY27 profit was reported down 12% year on year, despite revenue growth of 13.77% and EBITDA growth of 22%. The differing periods and measures make it important not to treat annual growth as a substitute for current-quarter momentum.
At March 2026, total assets were ₹20,873 crore, net worth ₹14,349 crore, and liabilities-to-assets 31.26%, up from 29.72% a year earlier. The fundamentals dataset flags a quick ratio of 1.86 versus 4.8 for the sector; this is a relative liquidity concern, though not by itself evidence of a cash shortfall.
Ownership and options positioning
At September 2026, promoter holding was 49.7%. Mutual-fund ownership rose to 17.79% from 16.71% in June, while other DII holding fell to 5.04% from 5.93%; FII holding was 10.32%, down 0.10 percentage point quarter on quarter.
ALKEM has listed options. The nearest displayed expiry is 23 November 2026; the chain showed put-call ratio 0.49 and max pain at ₹5,200. Open interest was relatively concentrated around the ₹5,000 put and ₹5,200 call strikes, but overall displayed open interest was modest. Treat these as a thin snapshot, not dependable support or resistance—especially around a company-specific regulatory headline.
What to watch
Any detailed company or regulatory disclosure on the warning letter, observations, remediation plan, and response timelines.
Whether Daman continues supplying US products and whether any product approvals or shipments are affected.
Follow-up regulatory outcomes, including any inspection or compliance update; the available data does not establish a resolution timeline.
Subsequent US sales, quarterly margins, and management commentary on manufacturing alternatives and remediation costs.
Price behaviour around the chart’s ₹5,030 and ₹5,301 reference levels, while recognising that headline risk can override technical levels.
Market and fundamentals figures are tool snapshots for 19 November 2026; the facility exposure and company response are as reported in the supplied story and retrieved news summary. This is analysis, not a price forecast or investment recommendation.
The data behind this
What edge looked up while writing this, as of the time above.
Alkem Laboratories Ltd. is an India-based pharmaceutical company engaged in the development, manufacturing, and sale of pharmaceutical products. The Company operates in a single business segment-Pharmaceuticals. It produces branded generics, generic drugs, active pharmaceutical ingredients (APIs), and nutraceuticals, which it markets in India and international markets. It has a portfolio of approximately 800 brands in India and maintains a presence in over 40 international markets, with the United States being its key focus market. Its offerings include therapies, prescription (Rx) products, and Alkem generics. Its therapy offerings cover multiple medical fields, including anti-infectives, anti-osteoporosis, cardiology, neurology, dermatology, diabetology, gastroenterology, gynecology, oncology, ophthalmology, respiratory care, rheumatology, and urology. The Company’s subsidiaries include Ascend Laboratories (Pty) Ltd, Pharmacor Pty Limited, Alkem Laboratories Corporation, and others.
Price
Rs 5,146
Day change
-1.46%
Day range
5,115 - 5,233.5
Volume
2L
P/E
29.73 (sector -45.24)
P/B
4.18 (sector 4.25)
ROA
9.08% (sector 1.19%)
ROE
13.91% (sector -0.4%)
ROCE
17.87% (sector 15.44%)
Quick Ratio
1.86 (sector 4.8)
EV/EBITDA
17.59 (sector 22.8)
Pros
P/B at 4.18 vs sector 4.2 (better than sector)
ROA at 9.08% vs sector 1.19% (better than sector)
ROE at 13.91% vs sector -0.4% (better than sector)
ROCE at 17.87% vs sector 15.44% (better than sector)
EV/EBITDA at 17.59 vs sector 22.74 (better than sector)
Net profit CAGR 32.71% across 4 annual periods
Concerns
Quick Ratio at 1.86 vs sector 4.8 (worse than sector)
Liabilities/assets 31.26% in Mar 2026 vs 29.72% in Mar 2025
DII (other) holding 5.04% in Sep 2026 (-0.89 pts)
Fundamentals Profit Loss4 items
Fundamentals Profit Loss results
Revenue Change Percent
Net Profit Change Percent
Operating Margin Percent
Net Margin Percent
Period
Revenue
13.65
6.19
18.77
15.38
Mar 2026
15,295.62
3.7
22.33
18.78
16.47
Mar 2025
13,458.26
9.84
79.92
15.59
13.96
Mar 2024
12,978.42
-
-
11.04
8.52
Mar 2023
11,815.34
Fundamentals Balance Sheet4 items
Fundamentals Balance Sheet results
Period
Total Assets
Total Liabilities
Net Worth
Asset Growth Percent
Liabilities To Assets Percent
Mar 2026
20,872.97
6,524.04
14,348.93
17.99
31.26
Mar 2025
17,691.1
5,257.47
12,433.63
13.59
29.72
Mar 2024
15,574.9
4,860.5
10,714.4
13.22
31.21
Mar 2023
13,756.65
4,321.65
9,435
-
31.41
Fundamentals Shareholding5 items
Fundamentals Shareholding results
Category
Label
Latest
Previous
Delta Percent Points
History
promoters
Promoters
49.7
49.7
0
4 items
fii
FII
10.32
10.42
-0.1
4 items
other_dii
DII (other)
5.04
5.93
-0.89
4 items
retail_and_other
Retail & others
17.15
17.25
-0.1
4 items
mutual_funds
Mutual funds
17.79
16.71
1.08
4 items
Written by snipy edge, an AI market analyst, from the story above and live market data at the time shown. For information only. This is not investment advice or a recommendation to buy or sell any security.